If you have been reading about melanocortin receptors and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
KH-001 is an atypical serotonin reuptake inhibitor (SRI) and phosphodiesterase (PDE) inhibitor which is under development for the treatment of premature ejaculation. It is taken on-demand orally. The drug is a purified alkaloid derived from the South African plant Sceletium tortuosum (kanna). It is said to be selective and to have high potency as a serotonin reuptake inhibitor and phosphodiesterase inhibitor. In addition, KH-001 has atypical properties as a serotonin reuptake inhibitor, including a rapid onset of therapeutic effectiveness rather than requiring chronic administration. KH-001 has been found to increase latency to ejaculation in male rats treated acutely with para-chloroamphetamine (PCA) to induce ejaculation. The pharmacokinetics of KH-001 in humans have been studied. It showed a rapid onset and a short duration. The drug is described as a potential first-in-class medication. KH-001 is under development by Kadence Bio (formerly Kanna Health). As of November 2024, it is in phase 1 clinical trials. Phase 2 trials were planned to begin in 2025. The chemical structure of KH-001 does not yet appear to have been disclosed. However, Kanna Health patented synthetic analogues of mesembrine with activity as serotonin reuptake inhibitors in 2023, with KH-001 being indicated as one of the compounds in the patent.
The two substrates of this enzyme are (1R,6R)-1,6-dihydroxycyclohexa-2,4-diene-1-carboxylic acid and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are catechol, carbon dioxide, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is (1R,6R)-1,6-dihydroxycyclohexa-2,4-diene-1-carboxylate:NAD+ oxidoreductase (decarboxylating). Other names in common use include 3,5-cyclohexadiene-1,2-diol-1-carboxylate dehydrogenase, 3,5-cyclohexadiene-1,2-diol-1-carboxylic acid dehydrogenase, dihydrodihydroxybenzoate dehydrogenase, DHBDH, cis-1,2-dihydroxycyclohexa-3,5-diene-1-carboxylate dehydrogenase, 2-hydro-1,2-dihydroxybenzoate dehydrogenase, cis-1,2-dihydroxycyclohexa-3,5-diene-1-carboxylate:NAD+, oxidoreductase, and dihydrodihydroxybenzoate dehydrogenase. This enzyme participates in benzoate degradation via hydroxylation and benzoate degradation via coa ligation.
Natural viral diseases, such as myxomatosis and rabbit hemorrhagic disease, have been used to help control pest populations. Over time the surviving pests become resistant, leading researchers to look at alternative methods. Genetically modified viruses that make the target animals infertile through immunocontraception have been created in the laboratory as well as others that target the developmental stage of the animal. There are concerns with using this approach regarding virus containment and cross species infection. Sometimes the same virus can be modified for contrasting purposes. Genetic modification of the myxoma virus has been proposed to conserve European wild rabbits in the Iberian peninsula and to help regulate them in Australia. To protect the Iberian species from viral diseases, the myxoma virus was genetically modified to immunize the rabbits, while in Australia the same myxoma virus was genetically modified to lower fertility in the Australian rabbit population. Outside of biology scientists have used a genetically modified virus to construct a lithium-ion battery and other nanostructured materials. It is possible to engineer bacteriophages to express modified proteins on their surface and join them up in specific patterns (a technique called phage display). These structures have potential uses for energy storage and generation, biosensing and tissue regeneration with some new materials currently produced including quantum dots, liquid crystals, nanorings and nanofibres.
Both the caps and the stems contain psychoactive compounds, although the caps consistently contain more. The spores of these mushrooms do not contain psilocybin or psilocin. The total potency varies greatly between species and even between specimens of a species collected or grown from the same strain. Because most psilocybin biosynthesis occurs early in the formation of fruit bodies or sclerotia, younger, smaller mushrooms tend to have a higher concentration of the drug than larger, mature mushrooms. In general, the psilocybin content of mushrooms is quite variable (ranging from almost nothing to 2.5% of the dry weight) and depends on species, strain, growth and drying conditions, and mushroom size. Cultivated mushrooms have less variability in psilocybin content than wild mushrooms. The drug is more stable in dried than fresh mushrooms; dried mushrooms retain their potency for months or even years, while mushrooms stored fresh for four weeks contain only traces of the original psilocybin. The psilocybin contents of dried herbarium specimens of Psilocybe semilanceata in one study were shown to decrease with the increasing age of the sample: collections dated 11, 33, or 118 years old contained 0.84%, 0.67%, and 0.014% (all dry weight), respectively. Mature mycelia contain some psilocybin, while young mycelia (recently germinated from spores) lack appreciable amounts. Many species of mushrooms containing psilocybin also contain lesser amounts of the analog compounds baeocystin and norbaeocystin, chemicals thought to be biogenic precursors.
There are nine subtilisin homologs in mammals; in addition to proprotein convertase 1 and 2, other members of this enzyme family include furin, PACE4, PC4, PC5/6, PC7/8, PCSK9, and SKI1/S1P. Proprotein convertase 1 converts prorenin into renin.
Sources: en.wikipedia.org
The Navier–Stokes equations ( nav-YAY STOHKS) describe the motion of viscous fluids. This system of partial differential equations was named after Claude-Louis Navier and George Gabriel Stokes, who developed them over a few decades of progressive work, from 1822 (Navier) to 1842–1850 (Stokes). Siméon Denis Poisson independently achieved the same results. The Navier–Stokes equations mathematically express momentum balance for Newtonian fluids and make use of the conservation of mass. They are sometimes accompanied by an equation of state relating pressure, temperature and density. They arise from applying Newton's second law to fluid motion, together with the assumption that the stress in the fluid is the sum of a diffusing viscous term (proportional to the gradient of velocity) and a pressure term—hence describing viscous flow. The Navier–Stokes equations generalize the Euler equations which only consider inviscid flow. The Navier–Stokes equations are of great scientific and engineering interest because they may be used to model a wide variety of scenarios. In their full or simplified forms, they can assist in the design of aircraft and cars, the study of blood flow, the design of power stations, the analysis of pollution, and many other problems. Coupled with Maxwell's equations, they comprise the fundamentals of magnetohydrodynamics. The Navier–Stokes equations are also of great interest to pure mathematics.
In October 2022, 777 Partners bought a minority stake in Melbourne Victory FC of the Australian A-League Men for AU$8.7 million. The following January, the club's shareholders voted in favor of allowing 777 Partners to secure up to 70% over the next five years, in exchange for AU$30 million in investment. The voluntary administration of 777 Partners' Australian airline Bonza in 2024 meant that Melbourne Victory were sponsored by AIA Group for the playoffs that year, before a long-term deal with Turkish Airlines could begin in 2025.
Reek of Putrefaction is the debut studio album by English extreme metal band Carcass. It was released by Earache Records on 28 July 1988. It is considered the first release in the goregrind genre, which the band pioneered.
They acknowledged that kimchi and pao cai are two different foods, where "Kimchi refers to a kind of fermented cabbage dish that plays an integral role in Korean cuisine, while pàocài, or Sichuan pàocài, refers to pickled vegetables that are popular originally in Southwest China's Sichuan Province, but now in most parts of northern China." Global Times also reported that Baidu Baike, a Chinese online encyclopedia, removed the controversial phrase "Korean kimchi originated from China" after the request. According to Sojin Lim, co-director of the Institute of Korean Studies of the University of Central Lancashire, Korean kimchi is often called pao cai in China, but China has its own Sichuanese fermented vegetable dish that it also calls pao cai. In 2021, the South Korean Ministry of Culture, Sports and Tourism subsequently presented the guidelines to set the term xīnqí (辛奇) as the new proper Chinese translation of kimchi, while pàocài was no longer the acceptable translation. However, CNN reported that the new Chinese translation of kimchi was unpopular with both Chinese and Korean netizens, and that some Chinese people complained that they do recognize the difference between dishes, but do not like to be told how to translate Kimchi in Chinese. There were also complaints among Koreans that Korea is appropriating their own traditional culture for the Chinese, by trying to promote a Chinese term for Kimchi which does not have an authentic Korean sound.
Outside Romania, public audiences in Western Europe initially projected generally idealistic notions of revolution on the country; the legacies of the French Revolution were fresh on people's minds in 1989 during its two-hundredth anniversary. However, as violence continued into 1990 and reports reached the West of mass casualties, this projected narrative shifted into a less sympathetic one characterized by disappointment in and suspicion of the revolution's direction.
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.